BrainStorm Cell Therapeutics
Sub-category: Tissue Engineering & Cell Therapy
Medical field: Neurology and Degenerative Disease
BrainStorm is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).
BrainStorm's novel stem cell treatment, NurOwnâ, induces the patient's mesenchymal stem cells (MSC) to secrete elevated levels of neurotrophic factors. These neuron-supporting cells are then transplanted back into the patient's spine and/or muscles. The company treated 26 patients in two clinical trials conducted at Hadassah Medical Center in Jerusalem, and is currently launching a multi-center Phase II ALS clinical trial in the USA. The company holds the rights to develop and commercialize NurOwn through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.
|Chaim Lebovits, CEO|
|Rehov Basel 12, Peatch Tikva|
|972-3-923-6384 ext 111|
To update your company data, click here.